Tandem Diabetes reviews

Terrible strategic visioning last few years especially for the one product with the most users. Tech debt caused as a result of not wanting to further innovate causing a deep hole proving difficult to get out of. Unrealistic timelines without the resources to support it. If one issue occurred prior to the next launch the whole ship would go down because the company was inadequately supported to handle problems. Upper management would make it seem like this wasn’t their problem to solve, either. Terrible employee managers and LOTS of reorganizing on the product side leading to decreased morale and just lost positivity for a product many truly believed in. Unsupportive managers when personal issues would arise leading to even further decreased morale. Being asked if you’re expecting to take more time off work outside of bereavement after a death in the family is inhumane. Workers are not robots. And finally, hiring people from Amazon and other tech companies is not a great way to drive innovation at a medical device company helping people with diabetes. This isn’t selling products with next day shipping. It’s slightly more complicated than that, and tech experts are not the right fight in this world because this world isn’t just software development. There are real people using the product with a lifelong disease.

New leadership hired in FY '21-'22 were brought in to help the company grow to a larger scale. Tandem is a medical device company, but this new leadership cohort primarily ran the department like a software company. They couldn't even do that right, and instead of accountability, they laid off hardworking (including longtime) employees in multiple waves. Rather than focusing on what made us successful, leadership caved to investor pressure, and that in turn worsened our company performance. They transformed Tandem from a patient-first company to an investor-first company and we all paid the price. Equity (in the form of stock) is no longer offered to employees.